Ad
ANTX - AN2 Therapeutics Stock Trading
About | AN2 Therapeutics Inc. (NYSE:ANTX)
None
Quote | AN2 Therapeutics Inc. (NYSE:ANTX)
| Last: | $ |
|---|---|
| Change Percent: | -1.27% |
| Open: | $57.76 |
| Close: | $56.86 |
| High: | $58.14 |
| Low: | $56.86 |
| Volume: | 315,708 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | AN2 Therapeutics Inc. (NYSE:ANTX)
-
Grant from Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant...
-
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ...
Message Board Posts | AN2 Therapeutics Inc. (NYSE:ANTX)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $ANTX News Article - AN2 Therapeutics to Present at Upcoming Investor Conferences | whytestocks | investorshangout | 11/02/2022 8:20:48 PM |
| whytestocks: $ANTX News Article - NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million | whytestocks | investorshangout | 09/29/2022 2:05:48 PM |
| whytestocks: $ANTX News Article - AN2 Therapeutics Reports Second Quarter 2022 Financial Results and | whytestocks | investorshangout | 08/11/2022 8:40:52 PM |
| whytestocks: $ANTX News Article - AN2 Therapeutics Reports First Quarter 2022 Financial Results and | whytestocks | investorshangout | 05/10/2022 8:35:52 PM |
| whytestocks: $ANTX News Article - AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Direc | whytestocks | investorshangout | 05/09/2022 12:30:49 PM |
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
Ad
-
Grant from Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant...
-
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ...
-
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indic...